Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of 14C-Labeled Isavuconazonium Sulfate in Healthy Males
NCT02059590Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Apr 2013
- Primary completion
- Apr 2013
- Modality
- Prodrugs/Conditional Activator Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of isavuconazonium in invasive aspergillosis (IA) and mucormycosis, sponsored by Astellas Pharma. Primary endpoints: Area under the concentration-time curve from time of dosing to infinity for radioactivity in whole blood and plasma, Maximum concentration for radioactivity in whole blood and plasma and 4 more. Started Apr 2013; status: completed.
02
Drugs
isavuconazonium
03
Conditions
invasive aspergillosis (IA)mucormycosis
Beyond the preview
Go deeper on NCT02059590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02059590.